Visiox
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Visiox Pharma is a Tarrytown, New York biopharmaceutical company focused on developing and commercializing ophthalmic drugs for highly prevalent eye diseases. Its lead assets include PDP-716, a novel once-daily brimonidine formulation using the patented TearAct delivery technology for glaucoma, and SDN-037, a twice-daily topical difluprednate corticosteroid for post-surgical inflammation. The company also commercializes Omlonti (omidenepag isopropyl), an EP2 receptor agonist for open-angle glaucoma and ocular hypertension. It is led by CEO Ryan Bleeks and founder Zachary Rome.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Seed round
Visiox closed a $7 million seed round funded by the founding partners and an exclusive group of ophthalmic industry leaders, to finalize and submit NDAs for its lead assets, manufacture initial inventory and build commercial infrastructure.
- Regulatory progress
The company submitted its NDA for once-daily brimonidine for glaucoma in October 2022, and the FDA accepted the NDA in December 2022.
- Public listing
In December 2023 Visiox announced a business combination with PowerUp Acquisition Corp that would list the company on Nasdaq, planning to launch Omlonti in early 2024 and PDP-716 in early 2025. No published evidence of a shutdown was found.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.